3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase NA
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
22
Myelodysplastic Syndromes
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma
12
Leukemia
10
Multiple Myeloma
9
Hodgkin Disease
9
Neuroblastoma
8
Sarcoma
7
Lymphoma, Non-Hodgkin
6
Sarcoma, Ewing
5
Primary Myelofibrosis
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Wilms Tumor
4
Rhabdomyosarcoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Neoplasms
4
Graft vs Host Disease
4
Congenital Abnormalities
4
Central Nervous System Neoplasms
4
Astrocytoma
4
Testicular Neoplasms
3
Retinoblastoma
3
Optic Nerve Glioma
3
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
Busulfan
×
Clear all
NCT02660281
2021-11-03
HaploOnly
University of Rochester
Phase 1
Completed
74 enrolled